 I wrote about Novo Nordisk a few months back, and called the company overvalued and a Hold. Its time to update that thesis in todays market, and following a 5 drop. The company is still expensive, but we should be aware of the fact that Novo Nordisk does deserve a fair bit of premium here - because of the companys quality. 